Integra LifeSciences | IART - Cash And Equivalent


Integra LifeSciences reported $232.19M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 7.51B 560M Sep/2025
AtriCure USD 147.86M 30.07M Sep/2025
Baxter International USD 1.73B 40M Sep/2025
Becton, Dickinson and Co. USD 641M 94M Sep/2025
Boston Scientific USD 1.28B 741M Sep/2025
CONMED USD 38.93M 4.99M Sep/2025
Cooper Companies USD 124.9M 13.3M Jun/2025
Dexcom USD 1.84B 676.7M Sep/2025
Edwards Lifesciences USD 2.69B 587.2M Sep/2025
Globus Medical USD 229.45M 231.82M Jun/2025
Hologic USD 2.17B 208.5M Dec/2025
Insulet USD 757.4M 364.2M Sep/2025
Integra LifeSciences USD 232.19M 14.27M Sep/2025
Intuitive Surgical USD 9.03B 601.6M Dec/2025
J&J USD 18.23B 10.35B Sep/2025
Medtronic USD 1.28B 9M Sep/2025
Merit Medical Systems USD 392.46M 50.64M Sep/2025
Stryker USD 3.26B 881M Sep/2025
Tandem Diabetes Care USD 91.95M 27.83M Sep/2025
Teleflex USD 354M 100.3M Sep/2025
Zimmer Biomet Holdings USD 1.29B 735.8M Sep/2025